This case report presents a comprehensive account of the reversal of Type 2 Diabetes Mellitus (T2DM) through a structured, integrative intervention centered on functional nutrition, targeted supplementation, detoxification support, and lifestyle modification. The report challenges the conventional view of T2DM as an inevitably progressive and irreversible disease, instead framing it as a dynamic metabolic condition driven by modifiable upstream factors such as insulin resistance, chronic inflammation, hepatic dysfunction, immune dysregulation, and lifestyle-related metabolic stress.

The subject of the case is a 59-year-old woman with a complex medical history spanning more than a decade. Her health challenges began with chronic asthma secondary to aspergillosis, accompanied by nasal polyps, recurrent respiratory infections, fungal skin conditions, and persistent immune activation. Over time, this chronic inflammatory and infectious burden contributed to metabolic deterioration, culminating in a diagnosis of Type 2 Diabetes Mellitus in November 2022. Despite pharmacological treatment with metformin and an active lifestyle that included regular exercise, her glycaemic control remained poor, energy levels declined, and additional metabolic complications emerged, including dyslipidaemia, suspected fatty liver disease, and intermittent hypertension. The patient sought a sustainable, root-cause–oriented solution with the goals of improving metabolic health, reducing medication dependence, restoring energy, and addressing her long-standing respiratory issues.

Baseline investigations revealed significant metabolic and inflammatory dysregulation. Glycaemic markers were markedly elevated, with an HbA1c of 8.2%, fasting blood glucose of 122.5 mg/dL, and fasting insulin indicative of insulin resistance. Lipid abnormalities, elevated triglycerides, fatty liver index, and deranged liver enzymes suggested hepatic insulin resistance and metabolic overload. Inflammatory and immune markers, including ferritin, neutrophils, and monocytes, reflected chronic immune activation, while hematological parameters pointed toward vascular and endothelial stress contributing to hypertension risk.

The intervention was designed to address these interconnected dysfunctions rather than focusing solely on glucose reduction. A customized functional nutrition protocol formed the foundation of care. This involved the elimination of dietary elements known to exacerbate insulin resistance, inflammation, and immune stress, including refined flours, wheat, refined sugars, industrial seed oils, soy, corn, and most dairy products. These were replaced with low-glycaemic traditional grains such as millets, controlled carbohydrate portions, high-quality protein sources, and metabolically supportive fats. Structured meal timing and composition were used to stabilize circadian glucose regulation and reduce glycaemic variability, with particular emphasis on protein-rich breakfasts and lighter, protein-centric dinners.

Targeted supplementation supported metabolic recovery at multiple levels. Foundational micronutrients addressed common deficiencies affecting insulin signaling, mitochondrial function, and immune balance, while specific agents such as berberine, chromium, and alpha-lipoic acid directly targeted insulin resistance and hepatic glucose output. A short-term detoxification phase supported gut health and reduced enterohepatic recirculation of metabolic and inflammatory by-products. Parallel to metabolic support, a focused antifungal and antimicrobial strategy was implemented to address the patient’s long-standing aspergillosis-related immune burden, recognizing the bidirectional relationship between chronic infection, inflammation, and insulin resistance.